Dianthus Therapeutics (NasdaqCM:DNTH) FY Conference Transcript

Dianthus Therapeutics FY Conference Summary Company Overview - Company: Dianthus Therapeutics (NasdaqCM:DNTH) - Event: 46th Annual TD Cowen Healthcare Conference - Date: March 03, 2026 Key Points Focus on Claseprubart - Dianthus is focusing on the drug claseprubart, which has shown promising Phase 2 data in myasthenia gravis (MG) trials, indicating a strong safety profile and efficacy at a dosage of 300 mg every two weeks [7][8] - The upcoming interim responder analysis for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a significant milestone, with expectations for additional responses above standard care [8][9] - The pivotal Phase 3 trial for CIDP involves switching patients from IVIG to claseprubart, aiming for a 1-point improvement on the MGC score to qualify for randomization into part B of the trial [9][10] Upcoming Milestones - Top-line results for the Phase 2 MMN trial are expected in the second half of the year, with comparisons to the efficacy data from empasiprubart [10][11] - The interim responder analysis for CIDP is anticipated in Q2, with a focus on maintaining a 40% to 50% response rate in part A of the trial [12][14] Competitive Landscape - The company is aware of recruitment challenges faced by competitors like Sanofi and argenx, which have struggled to enroll patients for their CIDP trials [20][24] - Dianthus believes its trial design is more patient-friendly, with less frequent visits and a higher likelihood of patient satisfaction, which may enhance recruitment [22][23] Safety and Efficacy Concerns - There are concerns regarding potential autoimmune activation and drug-induced lupus-like symptoms (DILS) associated with upstream inhibitors, but the company emphasizes that their drugs have not shown such effects in clinical trials [51][52] - The company is confident in the safety profile of claseprubart, having conducted thorough monitoring during trials [55][56] Comparison with Competitors - Dianthus is differentiating its approach by allowing refractory patients into its trials and not requiring a washout period from IVIG, which is seen as a more modern and effective trial design [103][105] - The company expects to demonstrate superior efficacy compared to competitors, particularly in the context of CIDP treatment, where IVIG has been the gold standard [44][105] Future Directions - The company plans to continue monitoring safety and efficacy closely, with a focus on moving quickly into Phase 3 trials if Phase 2 results are favorable [64][67] - There is an emphasis on understanding the balance of efficacy and safety in CIDP treatments, particularly in relation to the classical pathway inhibition [66][67] Additional Insights - The company is exploring the implications of its findings on the broader treatment landscape for CIDP and related conditions, aiming to establish itself as a leader in neuromuscular therapies [44][46] - The interim responder analysis will provide critical data on whether claseprubart can outperform existing treatments, potentially shifting treatment paradigms in CIDP [45][46]